What is (D) HD-V14 used for?

(D) HD-V14 is indicated for Atrial fibrillation for stroke prevention.

Who makes (D) HD-V14?

(D) HD-V14 is developed by National Taiwan University Hospital.

What development phase is (D) HD-V14 in?

(D) HD-V14 is FDA-approved (marketed).

What are the side effects of (D) HD-V14?

Common side effects include Bradycardia, Hypotension, Fatigue.

Last reviewed 2026-04-23 · How we verify

(D) HD-V14

National Taiwan University Hospital · FDA-approved active Small molecule

HD-V14 is a medication used to treat atrial fibrillation.

HD-V14 is a medication used to treat atrial fibrillation. Used for Atrial fibrillation for stroke prevention.

At a glance

Generic name	(D) HD-V14
Sponsor	National Taiwan University Hospital
Drug class	Class III antiarrhythmic agent, beta-blocker
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

It works by blocking certain electrical signals in the heart, helping to restore a normal heart rhythm. HD-V14 is a class III antiarrhythmic agent, specifically a beta-blocker.

Approved indications

Atrial fibrillation for stroke prevention

Common side effects

Bradycardia
Hypotension
Fatigue

Key clinical trials

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

(D) HD-V14 CI brief — competitive landscape report
(D) HD-V14 updates RSS · CI watch RSS
National Taiwan University Hospital portfolio CI